CareDx, Inc. (CDNA)Healthcare | Diagnostics & Research | Brisbane, United States | NasdaqGM
64.69 USD
-0.74
(-1.131%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:49 a.m. EDT
The immediate outlook is aggressively bullish, driven by a powerful technical rebound and overwhelming speculative interest in upside moves. The stock has staged a remarkable recovery from its lows, trading well above its 200-day average, and options flow confirms that traders are betting on further gains rather than protection. The high beta amplifies this momentum, making it a compelling near-term trade despite the elevated valuation multiples. However, the long-term picture remains mixed; while the company boasts exceptional top-line growth and a fortress balance sheet, the recent annual price decline suggests the market is still digesting past volatility or waiting for sustained profitability proof. The lack of any dividend support adds to the speculative nature of the current rally. Investors should view this as a high-conviction momentum play fueled by growth expectations, but remain cautious that the recent price dip was not entirely priced out of the narrative. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.089985 |
| AutoARIMA | 0.097686 |
| AutoETS | 0.255317 |
| MSTL | 0.272597 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.060 |
| Excess Kurtosis | 0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.522 |
| Revenue per Share | 8.886 |
| Market Cap | 3,346,686,976 |
| Trailing P/E | 30.80 |
| Forward P/E | 50.15 |
| Beta | 2.38 |
| Profit Margins | 24.23% |
| Previous Name | CareDx, Inc |
| Website | https://caredx.com |
As of Oct. 10, 2026, 6:49 a.m. EDT: Speculators are heavily positioned for upside continuation with massive open interest in out-of-the-money calls (65 strike) and deep out-of-the-money calls (90 strike) expiring in early 2027. Call volume significantly outweighs put volume in later expirations, indicating a bullish bias. However, there is notable defensive activity with significant put open interest at lower strikes (45-55) for the November 2026 expiration, suggesting some traders are hedging against a potential pullback before earnings.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.3649101 |
| Address1 | 8,000 Marina Boulevard |
| All Time High | 99.83 |
| All Time Low | 0.76 |
| Ask | 60.27 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,602,960 |
| Average Daily Volume3 Month | 1,324,939 |
| Average Volume | 1,324,939 |
| Average Volume10Days | 1,602,960 |
| Beta | 2.383 |
| Bid | 33.74 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 8.267 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 64.69 |
| Current Ratio | 4.581 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 67.73 |
| Day Low | 63.342 |
| Debt To Equity | 4.522 |
| Display Name | CareDx |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,443,400 |
| Earnings Call Timestamp Start | 1,785,443,400 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | 12,433,000 |
| Ebitda Margins | 0.027139999 |
| Enterprise To Ebitda | 240.674 |
| Enterprise To Revenue | 6.532 |
| Enterprise Value | 2,992,297,984 |
| Eps Current Year | 1.19833 |
| Eps Forward | 1.29 |
| Eps Trailing Twelve Months | 2.1 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 415 287 2450 |
| Fifty Day Average | 53.7895 |
| Fifty Day Average Change | 10.900501 |
| Fifty Day Average Change Percent | 0.2026511 |
| Fifty Two Week Change Percent | 336.49103 |
| Fifty Two Week High | 72.51 |
| Fifty Two Week High Change | -7.8199997 |
| Fifty Two Week High Change Percent | -0.107847184 |
| Fifty Two Week Low | 14.03 |
| Fifty Two Week Low Change | 50.660004 |
| Fifty Two Week Low Change Percent | 3.6108344 |
| Fifty Two Week Range | 14.03 - 72.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,405,603,800,000 |
| Float Shares | 49,455,330 |
| Forward Eps | 1.29 |
| Forward P E | 50.14729 |
| Free Cashflow | 112,160,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 761 |
| Fullday Change | -1.0199966 |
| Fullday Change Percent | -1.5589128 |
| Fullday Price | 64.69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.70582 |
| Gross Profits | 323,328,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03102 |
| Held Percent Institutions | 1.04085 |
| Implied Shares Outstanding | 51,734,223 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California. |
| Long Name | CareDx, Inc. |
| Market | us_market |
| Market Cap | 3,346,686,976 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9985914 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | 111,012,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,809,685,651 |
| Number Of Analyst Opinions | 6 |
| Open | 63.342 |
| Operating Cashflow | 93,658,000 |
| Operating Margins | 0.00195 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 415 287 2300 |
| Prev Name | CareDx, Inc |
| Previous Close | 65.43 |
| Price Eps Current Year | 53.98346 |
| Price Hint | 2 |
| Price To Book | 7.825088 |
| Price To Sales Trailing12 Months | 7.305757 |
| Profit Margins | 0.24234 |
| Quick Ratio | 4.355 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | -0.73999786 |
| Regular Market Change Percent | -1.1309764 |
| Regular Market Day High | 67.73 |
| Regular Market Day Low | 63.342 |
| Regular Market Day Range | 63.342 - 67.73 |
| Regular Market Open | 63.342 |
| Regular Market Previous Close | 65.43 |
| Regular Market Price | 64.69 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 1,191,452 |
| Return On Assets | -0.00252 |
| Return On Equity | 0.29487 |
| Revenue Growth | 0.522 |
| Revenue Per Share | 8.886 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 51,734,223 |
| Shares Percent Shares Out | 0.1273 |
| Shares Short | 6,587,070 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,828,536 |
| Short Name | CareDx, Inc. |
| Short Percent Of Float | 0.1297 |
| Short Ratio | 5.19 |
| Source Interval | 15 |
| State | CA |
| Symbol | CDNA |
| Target High Price | 75.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 61.66667 |
| Target Median Price | 64.5 |
| Total Cash | 373,636,000 |
| Total Cash Per Share | 7.222 |
| Total Debt | 19,247,000 |
| Total Revenue | 458,088,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.1 |
| Trailing P E | 30.804764 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.3272 |
| Two Hundred Day Average Change | 34.3628 |
| Two Hundred Day Average Change Percent | 1.1330687 |
| Type Disp | Equity |
| Volume | 1,191,452 |
| Website | https://caredx.com |
| Zip | 94,005 |